| Similar Articles |
|---|
 |
BusinessWeek
September 11, 2006
Christopher Palmeri |
The Green Stamp Of Approval Architects and their clients are scrambling to win eco-friendly certification.   |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
Fast Company
October 1, 2007
Anya Kamenetz |
The Green Standard? Leadership in Energy and Environmental Design -- LEED -- buildings get lots of buzz, but the point is getting lost. |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
The Motley Fool
September 23, 2010
Ryan McBride |
Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault. |
The Motley Fool
September 11, 2010
Luke Timmerman |
Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce. |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
Pharmaceutical Executive
March 1, 2006
Sara Calabro |
Genzyme: The Price of Success Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism. |
The Motley Fool
August 26, 2004
Selena Maranjian |
It's Easy Being Green Companies can profit, not sacrifice, when protecting the environment. |
Chemistry World
October 5, 2010
Andrew Turley |
Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. |
